메뉴 건너뛰기




Volumn 35, Issue 10, 2012, Pages 1175-1180

Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; EMOLLIENT AGENT; INFLIXIMAB; KERATOLYTIC AGENT; METHOTREXATE; VITAMIN D DERIVATIVE;

EID: 84859905688     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05082.x     Document Type: Article
Times cited : (25)

References (17)
  • 1
    • 44649187924 scopus 로고    scopus 로고
    • Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
    • DOI 10.1016/j.cgh.2008.03.014, PII S1542356508002917
    • Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF,. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53. (Pubitemid 351783447)
    • (2008) Clinical Gastroenterology and Hepatology , vol.6 , Issue.6 , pp. 644-653
    • Peyrin-Biroulet, L.1    Deltenre, P.2    De Suray, N.3    Branche, J.4    Sandborn, W.J.5    Colombel, J.6
  • 2
    • 79958228566 scopus 로고    scopus 로고
    • Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease
    • Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard M-A,. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011; 60: 930-6.
    • (2011) Gut , vol.60 , pp. 930-936
    • Peyrin-Biroulet, L.1    Oussalah, A.2    Williet, N.3    Pillot, C.4    Bresler, L.5    Bigard, M.-A.6
  • 3
    • 78649713662 scopus 로고    scopus 로고
    • Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy
    • Rahier J-F, Buche S, Peyrin-Biroulet L, et al,. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010; 8: 1048-55.
    • (2010) Clin Gastroenterol Hepatol , vol.8 , pp. 1048-1055
    • Rahier, J.-F.1    Buche, S.2    Peyrin-Biroulet, L.3
  • 4
    • 63849251824 scopus 로고    scopus 로고
    • Long-term safety of infliximab for the treatment of inflammatory bowel disease: A single-centre cohort study
    • Fidder H, Schnitzler F, Ferrante M, et al,. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-8.
    • (2009) Gut , vol.58 , pp. 501-508
    • Fidder, H.1    Schnitzler, F.2    Ferrante, M.3
  • 5
    • 58849160468 scopus 로고    scopus 로고
    • Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register
    • Harrison MJ, Dixon WG, Watson KD, et al,. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68: 209-15.
    • (2009) Ann Rheum Dis , vol.68 , pp. 209-215
    • Harrison, M.J.1    Dixon, W.G.2    Watson, K.D.3
  • 6
    • 81355151359 scopus 로고    scopus 로고
    • Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: A new series and a review of 120 cases from the literature
    • Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR,. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011; 34: 1318-27.
    • (2011) Aliment Pharmacol Ther , vol.34 , pp. 1318-1327
    • Cullen, G.1    Kroshinsky, D.2    Cheifetz, A.S.3    Korzenik, J.R.4
  • 7
    • 84856302095 scopus 로고    scopus 로고
    • Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: Results of an open-label, active-controlled, randomized trial (RESTORE1)
    • Barker J, Hoffmann M, Wozel G, et al,. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165: 1109-17.
    • (2011) Br J Dermatol , vol.165 , pp. 1109-1117
    • Barker, J.1    Hoffmann, M.2    Wozel, G.3
  • 8
    • 68949149916 scopus 로고    scopus 로고
    • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
    • Menter A, Korman NJ, Elmets CA, et al,. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-85.
    • (2009) J Am Acad Dermatol , vol.61 , pp. 451-485
    • Menter, A.1    Korman, N.J.2    Elmets, C.A.3
  • 9
    • 84859891279 scopus 로고    scopus 로고
    • Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics
    • [Epub ahead of print]
    • Williet N, Pillot C, Oussalah A, et al,. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis 2011 [Epub ahead of print].
    • (2011) Inflamm Bowel Dis
    • Williet, N.1    Pillot, C.2    Oussalah, A.3
  • 10
    • 84858708450 scopus 로고    scopus 로고
    • Urinary tract infections in hospitalized inflammatory bowel disease patients: A 10-year experience
    • Peyrin-Biroulet L, Pillot C, Oussalah A, et al,. Urinary tract infections in hospitalized inflammatory bowel disease patients: a 10-year experience. Inflamm Bowel Dis 2012; 18: 697-702.
    • (2012) Inflamm Bowel Dis , vol.18 , pp. 697-702
    • Peyrin-Biroulet, L.1    Pillot, C.2    Oussalah, A.3
  • 11
    • 84859917921 scopus 로고    scopus 로고
    • Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: The Mayo Clinic experience, 1998 to 2010
    • [Epub ahead of print]
    • Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR,. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 2011 [Epub ahead of print].
    • (2011) J Am Acad Dermatol
    • Shmidt, E.1    Wetter, D.A.2    Ferguson, S.B.3    Pittelkow, M.R.4
  • 12
    • 0028899859 scopus 로고
    • Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators
    • Feagan BG, Rochon J, Fedorak RN, et al,. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 292-7.
    • (1995) N Engl J Med , vol.332 , pp. 292-297
    • Feagan, B.G.1    Rochon, J.2    Fedorak, R.N.3
  • 15
    • 63849102069 scopus 로고    scopus 로고
    • Review article: Anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease
    • Fiorino G, Allez M, Malesci A, Danese S,. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29: 921-7.
    • (2009) Aliment Pharmacol Ther , vol.29 , pp. 921-927
    • Fiorino, G.1    Allez, M.2    Malesci, A.3    Danese, S.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.